
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert reviews the epidemiology, clinical presentation, and differential diagnoses of AD in children, as well as the inflammatory processes driven by type 2 cytokines that lead to AD and its atopic comorbidities
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).